Publicaciones en las que colabora con ROSA MARIA MARTI LABORDA (20)

2023

  1. Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    STAR Protocols, Vol. 4, Núm. 4

2022

  1. M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors

    British Journal of Cancer

2021

  1. Brafv600e mutant allele frequency (Maf) influences melanoma clinicopathologic characteristics

    Cancers, Vol. 13, Núm. 20

  2. Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification

    Acta Dermato-Venereologica, Vol. 101, Núm. 11

2020

  1. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma

    Journal of Investigative Dermatology, Vol. 140, Núm. 6, pp. 1253-1265

  2. T-type calcium channels: A potential novel target in melanoma

    Cancers, Vol. 12, Núm. 2

2019

  1. In vitro cell migration, invasion, and adhesion assays: From cell imaging to data analysis

    Frontiers in Cell and Developmental Biology, Vol. 7, Núm. JUN

2018

  1. T-type calcium channels drive migration/invasion in BRAFV600E melanoma cells through Snail1

    Pigment Cell and Melanoma Research, Vol. 31, Núm. 4, pp. 484-495

2017

  1. Immunohistochemical analysis of T-type calcium channels in acquired melanocytic naevi and melanoma

    British Journal of Dermatology, Vol. 176, Núm. 5, pp. 1247-1258

2016

  1. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels

    Pigment Cell and Melanoma Research, Vol. 29, Núm. 3, pp. 352-371

2015

  1. Calcium channel expression and applicability as targeted therapies in melanoma

    BioMed Research International, Vol. 2015

2013

  1. T-type calcium channel blockers inhibit autophagy and promote apoptosis of malignant melanoma cells

    Pigment Cell and Melanoma Research, Vol. 26, Núm. 6, pp. 874-885

2012

  1. Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

    Molecular Oncology, Vol. 6, Núm. 5, pp. 530-541

  2. Functional expression of voltage-gated calcium channels in human melanoma

    Pigment Cell and Melanoma Research, Vol. 25, Núm. 2, pp. 200-212

  3. Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway

    International Journal of Cancer, Vol. 130, Núm. 4, pp. 967-978

  4. New therapeutic targets in melanoma

    Actas Dermo-Sifiliograficas, Vol. 103, Núm. 7, pp. 579-590

2009

  1. Expression of somatostatin receptors in human melanoma cell lines: Effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation

    Journal of International Medical Research, Vol. 37, Núm. 6, pp. 1813-1822

2008

  1. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells

    Anti-Cancer Drugs, Vol. 19, Núm. 2, pp. 115-124

  2. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines

    British Journal of Dermatology, Vol. 158, Núm. 3, pp. 496-504

  3. Targeted therapies in gynecologic cancers and melanoma

    Seminars in Diagnostic Pathology, Vol. 25, Núm. 4, pp. 262-273